Health Ministry Revamps Drug Rules to Boost Pharmaceutical Research

The Union Ministry of Health and Family Welfare has introduced significant amendments to the New Drugs and Clinical Trials (NDCT) Rules, 2019, aiming to reduce regulatory burdens and enhance the ease of doing business within the pharmaceutical sector. This change eliminates the requirement for pharmaceutical companies to obtain a test licence from the Central Drugs Standard Control Organization (CDSCO) for the manufacture of small quantities of drugs intended for research or analysis purposes. Instead, companies can now proceed with pharmaceutical development by submitting an online intimation to CDSCO, with exceptions for a limited category of high-risk drugs, including cytotoxic drugs, narcotic drugs, and psychotropic substances.

These reforms are projected to save a minimum of 90 days in the drug development life cycle, offering a substantial boost to pharmaceutical research and innovation. Furthermore, for categories where test licences remain necessary, the statutory processing timeline has been halved from 90 days to 45 days. This change is significant given that CDSCO processes approximately 30,000 to 35,000 test licence applications each year, indicating a considerable reduction in regulatory burden for a wide range of stakeholders.

Expediting Clinical Research Through Regulatory Changes

In a further effort to accelerate clinical research, the Ministry has removed the requirement for prior permission for specific categories of low-risk Bioavailability/Bioequivalence (BA/BE) studies. These studies can now be initiated based solely on a simple online intimation to CDSCO. This adjustment is expected to facilitate quicker starts for studies, especially for the generic pharmaceutical industry, which submits around 4,000 to 4,500 BA/BE study applications annually. The revised mechanism aims to significantly reduce procedural delays, enhancing the overall efficiency of the process.

To ensure smooth implementation of these amendments, dedicated online modules will be accessible via the National Single Window System (NSWS) and the SUGAM portal. These platforms will allow industry stakeholders to submit their intimations transparently and efficiently. The Ministry emphasizes that these regulatory reforms are designed to provide substantial benefits to all involved parties while upholding public health and safety standards.

Overall, the amendments are anticipated to streamline regulatory processing times, facilitating quicker initiation of BA/BE studies, drug testing, and examination for research purposes. The Ministry also noted that these changes will enable CDSCO to optimize its existing manpower, improving both efficiency and effectiveness in regulatory oversight.

The initiative is part of a broader strategy to foster research-led growth in the Indian pharmaceutical industry, aligning domestic regulations with global best practices. This alignment is aimed at strengthening India’s position as a preferred destination for pharmaceutical research and development on the global stage.